{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:59:36Z","timestamp":1788184776711,"version":"build-2803163510"},"reference-count":96,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am Soc Clin Oncol Educ Book"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Unresectable stage III non\u2013small cell lung cancer (NSCLC) represents a biologically and clinically heterogeneous group of tumors. Concurrent chemoradiotherapy (cCRT) has long been the cornerstone of treatment for patients who are medically inoperable or have unresectable disease because of extensive nodal involvement or local invasion. Despite the curative intent of this approach, only about 30% of patients survive 5 years. Recently, advances have been made in both radiation oncology and medical oncology to incorporate precision medicine techniques and individualize treatment for each patient. Advances in radiation delivery techniques, including intensity-modulated radiotherapy, image-guided radiotherapy, motion management strategies, and adaptive radiotherapy, have improved the precision of treatment to the tumor and lymph nodes while minimizing toxicity to surrounding normal tissues. The introduction of consolidation immunotherapy following CRT has fundamentally changed the treatment paradigm. The phase III PACIFIC trial established consolidation durvalumab as the standard of care, demonstrating significant improvements in progression-free survival (PFS) and overall survival (OS). Similarly, biomarker-driven strategies have begun to reshape management for oncogene-driven tumors. The phase III LAURA trial demonstrated a substantial PFS benefit with consolidation osimertinib in patients with\n                      <jats:italic toggle=\"yes\">EGFR<\/jats:italic>\n                      -mutated stage III NSCLC after definitive CRT. Ongoing research is focused on optimizing treatment sequencing, including induction chemoimmunotherapy approaches, radiation dose intensification strategies such as stereotactic boosts, and integration of targeted therapies for actionable genomic alterations. In this review, we summarize the current evidence guiding the management of unresectable stage III NSCLC, highlight advances in radiation and systemic therapies, and discuss emerging strategies aimed at improving locoregional control and long-term survival.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/edbk-26-518252","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T19:59:09Z","timestamp":1780516749000},"source":"Crossref","is-referenced-by-count":1,"title":["State-of-the-Art Advances and Management of Unresectable Locally Advanced (Stage III) Non\u2013Small Cell Lung Cancer"],"prefix":"10.1200","volume":"46","author":[{"given":"Parth","family":"Desai","sequence":"first","affiliation":[{"name":"Department of Hematology &amp; Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Edelman","sequence":"additional","affiliation":[{"name":"Department of Hematology &amp; Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5993-596X","authenticated-orcid":false,"given":"Sameera","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1916623"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.108061"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2025.06.023"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02528"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27779"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.0043"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2402614"},{"key":"e_1_3_2_10_2","volume-title":"Non-Small Cell Lung Cancer","author":"National Comprehensive Cancer N","year":"2026","unstructured":"National Comprehensive Cancer N: Non-Small Cell Lung Cancer. 2026. https:\/\/www.nccn.org"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr325"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199010043231403"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2543"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01162"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)71207-0"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2023.10.005"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.12.011"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrac057"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.10.003"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1437"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.07.036"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2017.07.036"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2016.08.032"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.prro.2023.04.014"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.69.1378"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1841"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/mp.17269"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jrr\/rrx040"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phro.2022.09.003"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2023.101275"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102184"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00320-6"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.01.005"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25087"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.4280"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2587"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8824"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182a02546"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.197"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.17.7840"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0130"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809697"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.106029"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.02.009"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.287"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.07.1148"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01768-1"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01080-4"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae071"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.09.020"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00036"},{"key":"e_1_3_2_54_2","first-page":"e264","article-title":"65O CheckMate 73L: A phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small-cell lung cancer","volume":"24","author":"Peters S","year":"2024","unstructured":"Peters S, Tan DSW, Gerber DE, et al: 65O CheckMate 73L: A phase 3 study comparing nivolumab plus concurrent chemoradiotherapy followed by nivolumab with or without ipilimumab versus concurrent chemoradiotherapy followed by durvalumab for previously untreated, locally advanced stage III non-small-cell lung cancer. Immuno Oncol Technol 24:e264-e268, 2024","journal-title":"Immuno Oncol Technol"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2026.01.010"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-01569"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30737-3"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-49873-y"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02822"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-01324"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1556-0864(25)00379-X"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304594"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.48364"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1779"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.021"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2019.07.008"},{"key":"e_1_3_2_67_2","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2019.1631475"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.218223"},{"key":"e_1_3_2_69_2","doi-asserted-by":"publisher","DOI":"10.21037\/ccts-20-88"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.07.014"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115302"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.8509"},{"key":"e_1_3_2_74_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00227"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2354160"},{"key":"e_1_3_2_76_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8609"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1794"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.081"},{"key":"e_1_3_2_79_2","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2343272"},{"key":"e_1_3_2_80_2","volume-title":"Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab","author":"Merck, Co I","year":"2024","unstructured":"Merck, Co I: Merck Provides Update on KeyVibe and KEYFORM Clinical Development Programs Evaluating Investigational Vibostolimab and Favezelimab Fixed-Dose Combinations with Pembrolizumab. 2024"},{"key":"e_1_3_2_81_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.8512"},{"key":"e_1_3_2_82_2","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-362"},{"key":"e_1_3_2_83_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.3569"},{"key":"e_1_3_2_84_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.4163"},{"key":"e_1_3_2_85_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2025.100890"},{"key":"e_1_3_2_86_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax0182"},{"key":"e_1_3_2_87_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170"},{"key":"e_1_3_2_88_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"e_1_3_2_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.068"},{"key":"e_1_3_2_90_2","article-title":"The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist)","volume":"43","author":"Wang Y","year":"2025","unstructured":"Wang Y, Wang J, Deng L, et al: The preliminary results of a randomized phase II trial evaluating induction toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab in bulky unresectable stage III non-small-cell lung cancer (InTRist). J Clin Oncol 43, 2025 (suppl 16; abstr 8012)","journal-title":"J Clin Oncol"},{"key":"e_1_3_2_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.067"},{"key":"e_1_3_2_92_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00627"},{"key":"e_1_3_2_93_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1897"},{"key":"e_1_3_2_94_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.077"},{"key":"e_1_3_2_95_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.09.1379"},{"key":"e_1_3_2_96_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310532"},{"key":"e_1_3_2_97_2","doi-asserted-by":"crossref","unstructured":"Paz-Ares LG Paz-Ares LG: A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced unresectable stage III non\u2013small-cell lung cancer (NSCLC). Paper presented at: 2023 ASCO Annual Meeting 2023","DOI":"10.1016\/S1556-0864(23)00386-6"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/EDBK-26-518252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T12:31:46Z","timestamp":1781008306000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/EDBK-26-518252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":96,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1200\/EDBK-26-518252"],"URL":"https:\/\/doi.org\/10.1200\/edbk-26-518252","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"e518252"}}